Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Recommendation of “Buy” by Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received an average rating of “Buy” from the thirteen brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $11.6364.

A number of equities research analysts recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Friday, March 27th. Canaccord Genuity Group raised their price objective on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, April 6th. Wall Street Zen lowered shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Needham & Company LLC raised their price objective on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, March 19th. Finally, Chardan Capital restated a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, March 19th.

Taysha Gene Therapies Trading Down 5.5%

NASDAQ TSHA opened at $6.30 on Friday. The firm has a market cap of $1.81 billion, a P/E ratio of -16.58 and a beta of 1.25. The company has a debt-to-equity ratio of 0.23, a current ratio of 14.04 and a quick ratio of 14.04. The stock’s 50-day moving average is $5.29 and its 200-day moving average is $4.99. Taysha Gene Therapies has a one year low of $2.25 and a one year high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Sell-side analysts anticipate that Taysha Gene Therapies will post -0.48 earnings per share for the current fiscal year.

Insider Transactions at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the sale, the insider owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. This trade represents a 14.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.78% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TSHA. Marex Group plc acquired a new position in shares of Taysha Gene Therapies during the 2nd quarter worth about $29,000. E Fund Management Co. Ltd. acquired a new position in Taysha Gene Therapies in the 2nd quarter valued at $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in Taysha Gene Therapies in the 3rd quarter valued at $40,000. Tower Research Capital LLC TRC grew its position in shares of Taysha Gene Therapies by 156.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after purchasing an additional 10,742 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Taysha Gene Therapies by 143.8% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock worth $43,000 after purchasing an additional 4,607 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.